ACHV | tickerfilter.com

Fundamental analysis

Profitability 8%

Dept financing 4%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.71%

1 Month

-15.96%

3 Months

-13.47%

6 Months

-18.32%

1 Year

3.27%

2 Year

56.61%

Key data

Stock price

$3.78

P/E Ratio

0.00

DAY RANGE

$3.74 - $3.80

EPS

$0.00

52 WEEK RANGE

$3.83 - $5.59

52 WEEK CHANGE

-$7.79

MARKET CAP

150.358 M

YIELD

N/A

SHARES OUTSTANDING

34.250 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

0.83

PUBLIC FLOAT

AVERAGE 10 VOLUME

$204,701

AVERAGE 30 VOLUME

$143,584

Company detail

CEO: John A. Bencich
Region: US
Website: achievelifesciences.com
Employees: 20
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company is based in Vancouver, Canada and has license agreements with Sopharma AD and University of Bristol.

ACHV - ACHIEVE LIFE SCIENCES, INC.